TACE vs. Surgery for Liver Cancer: Which Treatment is Best?
"Exploring the latest research on liver cancer treatments, including TACE and surgical options, to help you make informed decisions."
Hepatocellular carcinoma (HCC), a type of liver cancer, is a significant global health challenge, ranking among the most common and deadly cancers worldwide. In countries like China, which accounts for over half of all HCC cases, the disease poses an especially heavy burden. When HCC is diagnosed beyond the Milan criteria—meaning the tumor is larger or there are multiple tumors—treatment becomes more complex. Doctors must consider factors like the patient's liver function and the extent of the cancer to determine the best course of action.
Two common treatments for HCC beyond the Milan criteria are transarterial chemoembolization (TACE) and surgery (hepatectomy). TACE is a minimally invasive procedure that delivers chemotherapy directly to the tumor through the hepatic artery. This helps to block the tumor's blood supply, slowing its growth. Hepatectomy, on the other hand, involves surgically removing the portion of the liver containing the tumor.
Deciding between TACE and surgery can be difficult. Both have potential benefits and risks, and the best choice depends on the individual patient's situation. Fortunately, recent research is shedding light on which approach may lead to better outcomes. This article explores a study comparing TACE combined with radiofrequency ablation (RFA) to hepatectomy, offering insights into how these treatments stack up.
TACE with RFA vs. Hepatectomy: Weighing the Options
A study published in "Cancer Management and Research" compared the effectiveness of TACE combined with radiofrequency ablation (RFA) versus hepatectomy in patients with HCC beyond the Milan criteria. The study retrospectively analyzed data from 270 patients treated at a single institution between January 2012 and December 2013.
- Overall Survival: The 1-, 2-, 3-, and 5-year OS rates were significantly higher in the TR group (98.5%, 83.1%, 66.2%, and 37.1%, respectively) compared to the HT group (89.6%, 69.4%, 53.7%, and 30.3%, respectively). The median survival time was 46 months for the TR group and 38 months for the HT group.
- Progression-Free Survival: The median PFS was 21 months in the TR group and only 8 months in the HT group, indicating that TACE with RFA may delay cancer progression more effectively than surgery alone.
- Independent Factors: Multivariate analysis identified treatment method, tumor diameter and number, Child-Pugh classification, antiviral therapy, and alpha-fetoprotein levels as independent factors affecting OS rates. Treatment mode, tumor diameter, and number were the independent factors affecting PFS.
Making Informed Decisions About Liver Cancer Treatment
Navigating a liver cancer diagnosis can feel overwhelming. Understanding the available treatment options and the latest research is crucial for making informed decisions in partnership with your healthcare team. While this study suggests that TACE with RFA may be a superior option for HCC beyond the Milan criteria, it's essential to discuss your individual circumstances with your doctor. They can assess your liver function, tumor characteristics, and overall health to determine the most appropriate and effective treatment plan for you.